152 results about "Growth factor receptor" patented technology

Described herein are methods of treating or reducing the severity of thyroid eye disease (TED), as well as antibodies that bind and inhibit signaling through the insulin-like growth factor receptor 1, useful in the methods.

Provided herein, among other things, are polynucleotides comprising a nucleic acid encoding an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) and natural killer cells expressing the polynucleotides.

The invention provides a nanogel for rapid permeation of articular cartilage and responsive release of a growth factor, which is prepared by polymerizing a peptide fragment which can be cut by a substance (mainly enzyme) which can be specifically expressed on the surface of osteoarthritis cells or secreted into a matrix with the growth factor, an acrylamide monomer and a cationic micromolecule monomer. Unreacted monomer molecules are filtered out through an ultrafiltration tube or other filtering systems, so that the nanogel which can rapidly permeate into the deep part of articular cartilage and can be recognized and cut by enzyme highly expressed on the surface of osteoarthritis cells or secreted enzyme to release growth factors is prepared, and the effect of the growth factors can be more effectively exerted; the nanogel has strong cartilage infiltration capacity, can completely infiltrate cartilage with the thickness of 1mm within less than 3 days, can be cut by MT1-MMP protein specifically expressed on the surfaces of osteoarthritis cells, releases growth factors, is specifically combined with growth factor receptors on the surfaces of cartilage cells, and activates downstream signal channels, so that the proliferation of the cartilage cells is promoted, and the cartilage cell proliferation rate is increased. The cartilage matrix secretion is promoted, so that the cartilage matrix thickening effect is realized, and the osteoarthritis is prevented and treated.

The present invention relates to methods of treating colorectal cancer (CRC), such as metastatic colorectal cancer (mCRC) or unresectable colorectal cancer, in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody (e.g., a bispecific antibody) to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met).

To create an antibody that inhibits an immune checkpoint function based on interaction between VSIG4 and Siglec-7 and exhibits antitumor activity, and to provide an anti-tumor immune response activator which includes the antibody as an active ingredient.SOLUTION: The present invention provides an anti-tumor immune response activator including an antibody that inhibits intermolecular interaction between VSIG4 and Siglec-7 or a functional fragment thereof.SELECTED DRAWING: Figure 9

Systems and methods are disclosed for receiving a target electronic image corresponding to a target specimen, the target specimen comprising a tissue sample of a patient, applying a machine learning system to the target electronic image to identify a region of interest of the target specimen and determine an expression level of, category of, and / or presence of a biomarker in the region of interest, the biomarker comprising at least one from among an epithelial growth factor receptor (EGFR) biomarker and / or a DNA mismatch repair (MMR) deficiency biomarker, the machine learning system having been generated by processing a plurality of training images to predict whether a region of interest is present in the target electronic image, the training images comprising images of human tissue and / or images that are algorithmically generated, and outputting the determined expression level of, category of, and / or presence of the biomarker in the region of interest.

Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.

The invention relates generally to variant activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these variant anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

The invention provides a near-infrared fluorescent probe for detecting an active targeting vascular epidermal growth factor receptor as well as a preparation method and application of the near-infrared fluorescent probe, and relates to the field of organic fluorescent probe molecules. The probe provided by the invention can actively target a vascular endothelial growth factor receptor, can be quickly cleared in normal tissues, and can be detained at a tumor part for a long time, so that the effect of preparing an actual in-vivo diagnosis probe is achieved, and the probe has a good clinical application prospect and is developed and applied to clinical fluorescence-guided intraoperative navigation.

The present disclosure provides compounds that can specifically target a PDGFRα, and thereby, reduce and / or inhibit the activation of the receptor (“PDGFRα inhibitor”). The present disclosure also provides methods of treating a demyelinating disease using the disclosed PDGFRα inhibitors.

The present invention relates to agents for in vivo imaging and detection of platelet-derived growth factor receptor alpha (PDGFR alpha)-expressing cancers using oxiracemab antibodies and methods of use thereof, including methods for imaging cancer and methods for selecting a patient for treatment.

Substituted pyrrolo[2,3-d]pyrimidines as inhibitors for multi-resistant cancers are described herein. Also provided herein are methods of forming the compounds, methods for inhibiting aurora kinase A and / or aurora kinase B activity and epidermal growth factor activity, methods of treating, ameliorating, or preventing cancer, and uses of the compounds for inhibiting aurora kinase A and / or aurora kinase B activity and epidermal growth factor receptor kinase activity. The compounds are generally of the formulas as illustrated herein, including those of Formula (I-2) or a pharmaceutically acceptable salt thereof:wherein: X1 is N; X2 is N; X3 is —NH—; X4 is N or CR2; X5 is CH, CCH3, or CCOOH; L1 is —NR4—R1; L2 is NH2 or H; R1 is:R2 is H, COOH, a 5-membered heteroaryl, or X6R3; X6R3 is as described herein; R4 is H; R5 is as described herein; and m is 1, 2, 3, 4, or 5.

The present application belongs to the field of biomedical technology, and particularly relates to an axial length and growth trend evaluation method of eye axis based on PDGFRA gene and a PDGFRA enzyme activity control agent. The method comprises the following steps: 1) collecting an eye biological sample of a subject; 2) based on the expression level of PDGFRA gene of platelet-derived growth factor receptor alpha in the collected biological sample; 3) based on the expression level, calculating the axial length of the eye axis according to the quantitative relationship between the expression amount of PDGFRA and the axial length of the eye axis, and predicting the growth trend of the axial length of the eye axis through additional calculation. The technical scheme of the present application can effectively detect and evaluate the axial length of the eye axis, effectively judge the growth trend of the axial length of the eye axis, and directly and efficiently control the axial length of the eye axis and its growth trend through the existing drug components.

A method for enhancing an expression of insulin like growth factor 1 receptor in an umbilical cord mesenchymal stem cell is provided. The method includes culturing the umbilical cord mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the umbilical cord mesenchymal stem cell.

Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin receptor intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.

The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.

Provided herein are methods of treating an EGFR-positive (EGFR+) cancer in a subject in need thereof comprising administering a bispecific gamma delta (γδ)-T cell engager (BS-GDTE) comprising a first antigen-binding domain that specifically binds to EGFR and a second antigen-binding domain that binds to human Vδ2.

The invention discloses application of RMTE in preparation of a medicine for preventing and controlling grass carp reovirus. The hemorrhagic disease caused by the grass carp reovirus (GCRV) is a key bottleneck restricting healthy development of the grass carp breeding industry, and the current vaccine for treating the grass carp reovirus (GCRV) has the problems of unstable immune protection effect, low protection rate for crossing of strains of different genotypes and the like, so that the research and development process of antiviral drugs is slow. The invention discloses an influence and a potential mechanism of a rhodamine B-ethyl sulfide condensation compound (RMTE) on GCRV (Growth Factor Receptor Virus) infection. Results show that the RMTE can significantly inhibit expression of VP6 and VP7 genes in GCRV infected cells, can effectively relieve expression inhibition of GCRV on GPX4, Caspase and p53 genes and promote expression of the three genes, and prove that the RMTE has a significant inhibition effect on GCRV infection and plays an antiviral effect through multiple ways. Research results provide new potential drugs and theoretical basis for prevention and control of GCRV.

A binding domain having a binding specificty to human EGFR (epithelium growth factor receptor) comprises a VH domain and a VL domain, wherein the VH and VL domain each independently comprises a sequence having at least 90% sequence identify to an amino acid sequence as disclosed thereof. The application further provides antibodies comprising the binding domain.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).

The present invention relates to a novel heterocyclic compound which is a compound having FGFR protein activity. Specifically, the invention relates to a compound shown as a formula (II), or pharmaceutically acceptable salt, solvate, polymorphic substance or isomer thereof, and application of the compound in preparation of medicines for treating diseases related to FGFR (Factor Growth Factor Receptor).

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the adjuvant treatment after tumour resection of patients with epidermal growth factor receptor-mutation-positive (EGFRm) non-small cell lung cancer (NSCLC).

Modified natural killer (NK) cells or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express thrombopoietin receptors, erythropoietin receptors, or chimeric peptides comprising an extracellular domain, a transmembrane domain, and an intracellular domain including an intracellular signaling domain of an interleukin receptor. Methods for treating cancer subjects are also provided, comprising administering modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or an erythropoietin receptor agonist, and in some instances, in combination with interleukin-2, particularly reduced or low doses of IL-2.

The current disclosure address a need in the art by providing methods and compositions for treating migraines and certain pain-related disorders with a combination therapy. Accordingly, aspects of the disclosure relate to a method for treating a migraine, post-traumatic headache, or chronic pain syndrome patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator and a calcitonin gene-related peptide (CGRP) inhibitor. Further aspects relate to a composition comprising insulin-like growth factor-1 (IGF-1) and a CGRP inhibitor. Also provided are methods for treating fibromyalgia or chronic fatigue syndrome in a patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator.

Systems and methods are disclosed for receiving a target electronic image corresponding to a target specimen, the target specimen comprising a tissue sample of a patient, applying a machine learning system to the target electronic image to identify a region of interest of the target specimen and determine an expression level of, category of, and / or presence of a biomarker in the region of interest, the biomarker comprising at least one from among an epithelial growth factor receptor (EGFR) biomarker and / or a DNA mismatch repair (MMR) deficiency biomarker, the machine learning system having been generated by processing a plurality of training images to predict whether a region of interest is present in the target electronic image, the training images comprising images of human tissue and / or images that are algorithmically generated, and outputting the determined expression level of, category of, and / or presence of the biomarker in the region of interest.

The present invention relates to methods for the selection of a stable producer cell line expressing one or more protein(s) of interest (POIs), comprising the stable transfection of cells with a gene encoding a constitutively active variant of a growth factor receptor, respective methods for the expression of one or more POIs in such stable producer cell lines, and uses of a constitutively active variant of a growth factor receptor as selection marker in the cultivation of cells.

The present invention relates to a composition comprising an olaratumab antibody conjugated to a therapeutic radioisotope for the treatment of cancer expressing platelet-derived growth factor receptor alpha (PDGFR-alpha), and to a method of using the same.

The present invention belongs to the technical fields of biomedicine and molecular biology, and particularly relates to a single-chain fragment variable (scFv) targeting human platelet-derived growth factor receptor (PDGFR)-β and use thereof in chimeric antigen receptor (CAR)-T cell immunotherapy. In the present invention, a scFv sequence targeting a human-derived PDGFRβ antigen is first obtained by immunizing a mouse, and then a second-generation CAR is constructed based on this, and additionally a CAR-T cell is obtained via lentivirus infection. The CAR-T cell can effectively kill a PDGFRβ antigen-positive 293T cell. The present invention provides a brand-new idea for eliminating PDGFRβ-positive cells to treat chronic kidney diseases, chronic liver diseases, cardiovascular diseases and various tumor diseases including various organ fibrosis, and has extremely attractive further development value and application prospects.

The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GRB14 gene, as well as methods of inhibiting expression of GRB14, and methods of treating subjects that would benefit from reduction in expression of GRB14, such as subjects having a GRB14-associated disease, disorder, or condition, such as diabetes, using such dsRNA compositions.